Skip to main content
KAKEN PHARMACEUTIAL CO., LTD. logo

KAKEN PHARMACEUTIAL CO., LTD. — Investor Relations & Filings

Ticker · 4521 ISIN · JP3207000005 T Manufacturing
Open in API
Filings indexed 70 across all filing types
Latest filing 2026-04-22 Regulatory Filings
Country JP Japan
Listing T 4521

About KAKEN PHARMACEUTIAL CO., LTD.

https://www.kaken.co.jp/english/

Kaken Pharmaceutical Co., Ltd. is a research and development-driven company that develops, manufactures, and markets prescription pharmaceuticals, medical equipment, and agrochemicals. The company's primary focus is on pharmaceuticals, with significant expertise in dermatology, orthopedics, and surgery. Its portfolio of main products includes Clenafin for onychomycosis, Artz for osteoarthritis, Fiblast for wound healing, and Ecclock for primary axillary hyperhidrosis. Kaken's research and development efforts are concentrated on specific fields, including the immune system, nervous system, and infectious diseases, to create innovative drugs. The company also has business activities in real estate.

Recent filings

Filing Released Lang Actions
Johnson & Johnsonとのライセンス契約に係るマイルストン達成およびマイルストン収入の受領等に伴う2026年3月期連結業績予想修正に関するお知らせ
Regulatory Filings
2026-04-22 Japanese
確認書
Regulatory Filings Classification · 95% confidence The document is a 'Confirmation Letter' (Kakunin-sho) filed under the Financial Instruments and Exchange Act in Japan. It serves as an officer certification by the CEO confirming the accuracy of a semi-annual report. According to the 'Certification Rule', documents that are primarily officer certifications or attestations should be classified as Regulatory Filings (RNS), even if they reference a specific report type. H1 106
2025-11-13 Japanese
半期報告書－第106期(2025/04/01－2026/03/31)
Interim / Quarterly Report Classification · 100% confidence The document is a 'Semi-Annual Report' (半期報告書) filed by Kaken Pharmaceutical Co., Ltd. with the Kanto Local Finance Bureau. It contains detailed financial statements, including the balance sheet, income statement, and management analysis for the interim period ending September 30, 2025. It is a comprehensive financial report for a period shorter than a full fiscal year, fitting the definition of an Interim/Quarterly Report (IR). H1 2026
2025-11-13 Japanese
自己株券買付状況報告書（法２４条の６第１項に基づくもの）
Transaction in Own Shares Classification · 100% confidence The document is a 'Report on Purchase of Own Shares' (自己株券買付状況報告書) filed under the Financial Instruments and Exchange Act in Japan. It details the company's share buyback activity for the period of September 2025, including the number of shares acquired and the total cost. This aligns perfectly with the definition for 'Transaction in Own Shares' (POS).
2025-10-14 Japanese
自己株券買付状況報告書（法２４条の６第１項に基づくもの）
Transaction in Own Shares Classification · 100% confidence The document is a 'Report on Status of Acquisition of Treasury Shares' (自己株券買付状況報告書) filed under the Financial Instruments and Exchange Act. It details the company's share buyback activity for the period of August 2025. This falls directly under the category of 'Transaction in Own Shares' (POS).
2025-09-09 Japanese
自己株券買付状況報告書（法２４条の６第１項に基づくもの）
Transaction in Own Shares Classification · 100% confidence The document is a 'Report on Purchase of Own Shares' (自己株券買付状況報告書) filed under the Financial Instruments and Exchange Act in Japan. It details the company's share repurchase activity for the period of July 2025, including the number of shares acquired and the total cost. This falls directly under the category of 'Transaction in Own Shares' (POS).
2025-08-06 Japanese

Browse filings by year

12 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.